← Evidence map

ReviewVascular health and risk management2012

Differential pharmacology and benefit/risk of azilsartan compared to other sartans.

Theodore W Kurtz et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.

31 papers cite it

2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
this paperpooled ittrialcites it
Full record →Abstract, authors, funding and every citing paper · PMID 22399858